Brief Report About the Role of Hyperthermic Intraperitoneal Chemotherapy in a Prospective Randomized Phase 3 Study in Recurrent Ovarian Cancer From Spiliotis et al

2017 ◽  
Vol 27 (2) ◽  
pp. 246-247 ◽  
Author(s):  
Philipp Harter ◽  
Alexander Reuss ◽  
Jalid Sehouli ◽  
Luis Chiva ◽  
Andreas du Bois
Keyword(s):  
Ovarian Cancer ◽  
Intraperitoneal Chemotherapy ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Recurrent Ovarian Cancer ◽  
Phase 3

AbstractA published so-called phase 3 study regarding HIPEC in ovarian cancer raised multiple questions. This commentary focusses on the weakness of the publication and discusses this in detail.

scholarly journals Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer

Diagnostics ◽  
2020 ◽  
Vol 10 (1) ◽  
pp. 43 ◽  
Author(s):  
McKayla J. Riggs ◽  
Prakash K. Pandalai ◽  
Joseph Kim ◽  
Charles S. Dietrich
Keyword(s):  
Ovarian Cancer ◽  
Intraperitoneal Chemotherapy ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Residual Tumor ◽  
Recurrent Ovarian Cancer ◽  
Adjunctive Treatment ◽  
Intravenous Route ◽  
History Of ◽  
Systemic Side Effects ◽  
Chemotherapy Agents

Hyperthermic intraperitoneal chemotherapy (HIPEC) in conjunction with cytoreductive surgery (CRS) holds promise as an adjunctive treatment strategy in malignancies affecting the peritoneal surface, effectively targeting remaining microscopic residual tumor. HIPEC increases concentrations of chemotherapy directly within the peritoneal cavity compared with the intravenous route and reduces the systemic side effects associated with prolonged adjuvant intraperitoneal exposure. Furthermore, hyperthermia increases tissue penetration and is synergistic with the therapeutic chemotherapy agents used. In ovarian cancer, evidence is building for its use in both primary and recurrent scenarios. In this review, we examine the history of HIPEC, the techniques used, and the available data guiding its use in primary and recurrent ovarian cancer.

Sign in / Sign up

Export Citation Format

Share Document